Chromatin immunoprecipitation (ChIP) Sequencing Global Market Report 2024

The chip sequencing market size has grown rapidly in recent years. It will grow from $12.36 billion in 2023 to $13.89 billion in 2024 at a compound annual growth rate (CAGR) of 12.4%. The growth observed during the historical period can be attributed to advancements in understanding gene regulation, a rise in epigenetics studies, improvements in data analysis and bioinformatics tools, and the associated cost reduction and scalability in Chromatin Immunoprecipitation (ChIP) sequencing techniques.

The chip sequencing market size is expected to see rapid growth in the next few years. It will grow to $22.26 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The anticipated growth in the forecast period can be attributed to increased industry investment and competition, growing clinical adoption for diagnostic applications, a demand for biomarker discovery, rapid development in bioinformatics tools, and expanded applications in drug discovery using Chromatin Immunoprecipitation (ChIP) sequencing. Major trends expected during the forecast period include the translation of ChIP sequencing into clinical and diagnostic applications, a heightened focus on histone modifications, application in novel research areas, advancements in sample preparation techniques, and the integration of multi-omics approaches.

The growth of the chromatin immunoprecipitation (ChIP) sequencing market is expected to be driven by the increasing prevalence of prostate cancer. Prostate cancer, which originates in the prostate gland, is anticipated to contribute to the market's expansion. ChIP-seq plays a vital role in prostate cancer research by providing a comprehensive understanding of the molecular events influencing the disease. This information is crucial for advancing the understanding of its biology and developing more targeted therapeutic interventions. In January 2023, the American Cancer Society reported an estimated 288,300 new cases of prostate cancer and 34,700 deaths in the US, emphasizing the significance of ChIP-seq in addressing this health concern.

The growth of the chromatin immunoprecipitation (ChIP) sequencing market is expected to be propelled by the increasing adoption of personalized medicine. Personalized medicine, which tailors medical decisions to individual patient characteristics, relies on identifying specific genetic or epigenetic markers associated with diseases. ChIP sequencing proves to be a powerful tool in mapping epigenetic modifications crucial for understanding the genetic basis of diseases. In 2022, the approval of 37 novel molecular entities by the FDA's Center for Drug Evaluation and Research, with 34% designated as tailored medications by the Personalized Medicine Coalition, highlights the role of ChIP sequencing in advancing personalized medicine.

The high cost of ChIP-sequencing technology is anticipated to hinder market growth. The substantial expenses associated with ChIP-Seq experiments, approximately $550 per sample, may limit the number of samples processed, slowing down research progress. This cost factor may impede the technology's adoption in therapeutic settings where cost-effectiveness is a critical consideration. While ChIP-Seq is considered more cost-effective than alternative methods, its expense, influenced by factors such as genome size and sequencing depth, remains a limiting factor for broader implementation.

Major companies in the chromatin immunoprecipitation (ChIP) sequencing market are addressing consumer needs through innovative products, such as molecular electronics chips. These chips, utilizing single molecules or molecular assemblies for electronic functions, aim to enhance research capabilities. For instance, Roswell Biotechnologies launched the Roswell ME Chip in November 2021, offering a flexible and potent tool for examining oligos and biological dynamics related to DNA and polymerase binding. This chip's potential applications extend across various industries, including fundamental science, environmental monitoring, and healthcare.

In August 2021, ProPhase Labs Inc., a US-based biotechnology company, acquired Nebula Genomics for $14.6 million. This strategic acquisition aligns with ProPhase's goal to better support individuals seeking assistance in diagnosing genetically impacted conditions. Nebula Genomics, known for its web service analyzing ChIP-sequencing (ChIP-Seq) data, contributes to ProPhase's commitment to advancing genetic diagnostics for various health concerns.

Major companies operating in the chromatin immunoprecipitation (chip) sequencing market report are F. Hoffmann La Roche Ltd., Merck KGaA, Thermo Fisher Scientific Inc. , Becton Dickinson and Co., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc. , PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Bio-Techne Corp., BGI Genomics Co. Ltd., Promega Corporation, GenScript Biotech Corporation, Abcam plc, BioLegend Inc., Hamilton Co., Takara Bio Inc., Novogene Co. Ltd., Oxford Nanopore Technologies plc, Porvair Sciences Ltd. , Creative Biolabs Inc., Cell Signaling Technology Inc., GENEWIZ Inc., Zymo Research Corporation, CD Genomics, Active Motif Inc., Psomagen Inc., EpiCypher Inc.

North America was the largest region in the chromatin immunoprecipitation (ChIP) sequencing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chromatin immunoprecipitation (chip) sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the chromatin immunoprecipitation (chip) sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chromatin immunoprecipitation (ChIP) sequencing market consists of revenues earned by entities by providing services such as ChIP sample preparation, library preparation and sequencing, bioinformatics analysis, customization and consultation, data interpretation and reporting, and quality control, and assurance. The market value includes the value of related goods sold by the service provider or included within the service offering. The ChIP sequencing market also includes sales of ChIP kits, antibodies, DNA library preparation kits, sequencing kits, chromatin shearing equipment, and epigenetic modification kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The main types of ChIP sequencing include DNase-sequencing and Faire-sequencing. DNase-sequencing, commonly known as DNase-seq, is a molecular biology technique designed to assess the accessibility of DNA within the genome. It utilizes various technologies such as targeted sequencing, re-sequencing, whole genome sequencing, and whole exome sequencing for pre-sequencing, sequencing, and data analysis. The applications of DNase-seq encompass consumables and reagents, services, and other related components. The technique finds usage in academic research institutes, clinical research institutes, hospitals and clinics, pharmaceuticals and biotechnology companies, among others.

The chromatin immunoprecipitation (ChIP) sequencing market research report is one of a series of new reports that provides chromatin immunoprecipitation (ChIP) sequencing market statistics, including chromatin immunoprecipitation (ChIP) sequencing industry global market size, regional shares, competitors with a chromatin immunoprecipitation (ChIP) sequencing market share, detailed chromatin immunoprecipitation (ChIP) sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the chromatin immunoprecipitation (ChIP) sequencing industry. This chromatin immunoprecipitation (ChIP) sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.